The Norwegian ME Association donated on May 12th funds for two research projects.
One of the research projects is by Fluge, Mella and their team. They want to try and find more objective ways to measure changes in patients enrolled in clinical trials by continuous measurement of physical...
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
SUMMARY: Could the positive results of the early Fluge & Mella 2011 blinded phase II rituximab trial and 2015 open label phase II study be due to inadvertently including some Giardia lamblia ME/CFS patients in the cohort, from the 2004 Bergen Giardia...
B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
https://annals.org/aim/article-abstract/2729813/b-lymphocyte-depletion-patients-myalgic-encephalomyelitis-chronic-fatigue-syndrome-randomized...
Rituximab Serum Concentrations and Anti- Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome
Rekeland, Fluge, Mella et al
(only the abstract is available for now)
Findings
There were no significant differences in mean serum rituximab...
This thread has been split from the Stanford Community Symposium 2018 thread.
(Copied post)
I watched Drs Fluge and Hanson with a rest between them. Utterly loving Dr Fluge’s talk where he moved between talk of the patients and the data.
Didn’t understand a lot but someone?? talked of...
Rituximab (RituxME)
Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series
Øystein Fluge and Olav Mella
BMC Neurology
2009
Link to article
Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.